Hyderabad, India-based Natco Pharma, a generic drug maker, is planing to acquire Teva. The acquisition is said to be in relation to generic Copaxone indicated for multiple sclerosis.
Reportedly, Natco with Mylan have filed ANDA with the FDA for marketing of Copaxone clone in the US.
Additionally, Teva has also filed a citizen’s petition (CP) alleging that generic drug makers can’t show their drug is a precise copy of Copaxone — a fact that should preclude market approval, reported DNA.
Natco claims that the drug will offer a significant upside once its ANDA is approved by the regulator.